The nation of Zimbabwe has declined a major American health deal worth 367 million US dollars (£272m) over five years due to Washington's demand for confidential data.
This rejection came to light following a official document from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official representative later explained that the US was seeking health data for research and profit while refused to share the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for continued negotiations to reach a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Background
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court blocked a related deal with the US following legal challenges were filed about the security of citizens' health data.
After returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and accountability.
Based on statements, Sixteen nations in Africa have so far signed similar health pacts, constituting over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data for a long time, without any corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our citizens if a new disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending frameworks previously set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This mechanism is intended to guarantee that when a nation provides its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further discussions with our US partners on how future collaboration could be arranged in a way that honours the independence and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but suggested that talks must proceed considering much of the country's HIV programmes relied on international support.
"If specific concerns exist, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The halted deal emphasises the ongoing debate between receiving much-needed international aid and protecting national sovereignty in an increasingly data-driven world.